Literature DB >> 17296591

Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma.

Johannes J A Auwerda, Pieter Sonneveld, Monica P M de Maat, Frank W G Leebeek.   

Abstract

Prothrombotic coagulation abnormalities were analyzed in patients with untreated multiple myeloma. Increases in factor VIII, in von Willebrand factor (vWF) and a decrease in protein S were observed and these changes were strongly associated with disease stage. No difference in baseline coagulation parameters was found between patients with and without subsequent venous thromboembolism.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17296591     DOI： 10.3324/haematol.10454

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  20 in total

1.  Venous thromboembolism and cancer risk among elderly adults in the United States.

Authors:  Morgan A Marks; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03-08       Impact factor: 4.254

Review 2.  Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review.

Authors:  B T Samuelson Bannow; B A Konkle
Journal:  Thromb Res       Date:  2018-01-31       Impact factor: 3.944

3.  Is SCUBE1 helpful to predict the arterial thrombotic risk in patients with multi-ple myeloma: a preliminary study.

Authors:  E Akdoğan; T Ayaz; A Kırbaş; H Rakıcı
Journal:  Hippokratia       Date:  2019 Jan-Mar       Impact factor: 0.471

4.  Patients With Multiple Myeloma Have a Disbalanced Whole Blood Thrombin Generation Profile.

Authors:  Li Li; Mark Roest; Yaqiu Sang; Jasper A Remijn; Rob Fijnheer; Karel Smit; Dana Huskens; Jun Wan; Bas de Laat; Joke Konings
Journal:  Front Cardiovasc Med       Date:  2022-06-27

5.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Authors:  Waqas Rehman; Lisa M Arfons; Hillard M Lazarus
Journal:  Ther Adv Hematol       Date:  2011-10

6.  Plasma levels of phospholipase A2-IIA in patients with different types of malignancies: prognosis and association with inflammatory and coagulation biomarkers.

Authors:  Mario Menschikowski; Albert Hagelgans; Ulrich Schuler; Susanne Froeschke; Andrea Rosner; Gabriele Siegert
Journal:  Pathol Oncol Res       Date:  2013-06-01       Impact factor: 3.201

7.  Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Sigurdur Y Kristinsson; Thomas R Fears; Gloria Gridley; Ingemar Turesson; Ulf-Henrik Mellqvist; Magnus Björkholm; Ola Landgren
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

8.  Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.

Authors:  David C Johnson; Sophie Corthals; Christine Ramos; Antje Hoering; Kim Cocks; Nicholas J Dickens; Jeff Haessler; Harmut Goldschmidt; J Anthony Child; Sue E Bell; Graham Jackson; Dalsu Baris; S Vincent Rajkumar; Faith E Davies; Brian G M Durie; John Crowley; Pieter Sonneveld; Brian Van Ness; Gareth J Morgan
Journal:  Blood       Date:  2008-09-19       Impact factor: 22.113

9.  Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma.

Authors:  Marta Robak; Jacek Treliński; Krzysztof Chojnowski
Journal:  Med Oncol       Date:  2012-07-07       Impact factor: 3.064

10.  Nonsecretory multiple myeloma presenting as an intestinal tumor.

Authors:  Diana Triantafyllopoulou; Stuart Mellor; Catherine Cargo; Ioannis Gkikas; Jagdish Adiyodi; Ayub Ali Bin; Neil Sahasrabudhe; Margaret Rokicka
Journal:  Case Rep Hematol       Date:  2015-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.